{
    "Rank": 621,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00503841",
                "NCTIdAliasList": {
                    "NCTIdAlias": [
                        "NCT01654757"
                    ]
                },
                "OrgStudyIdInfo": {
                    "OrgStudyId": "CDR0000554965"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "P30CA022453",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/P30CA022453"
                        },
                        {
                            "SecondaryId": "WSU-2006-138"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "Barbara Ann Karmanos Cancer Institute",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer",
                "OfficialTitle": "A Pilot Study of the Effect of Erlotinib (Tarceva\u00ae) on Biomarkers in Estrogen Receptor Negative Breast Cancer Expressing the Epidermal Growth Factor Receptor and Interleukin 1\u03b1"
            },
            "StatusModule": {
                "StatusVerifiedDate": "April 2019",
                "OverallStatus": "Terminated",
                "WhyStopped": "All enrolled participants were screen failures, no data were collected for outcome measures.",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "December 2007"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "February 2010",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "May 2010",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "July 17, 2007",
                "StudyFirstSubmitQCDate": "July 17, 2007",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "July 19, 2007",
                    "StudyFirstPostDateType": "Estimate"
                },
                "ResultsFirstSubmitDate": "January 9, 2013",
                "ResultsFirstSubmitQCDate": "January 9, 2013",
                "ResultsFirstPostDateStruct": {
                    "ResultsFirstPostDate": "February 12, 2013",
                    "ResultsFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "April 22, 2019",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "April 30, 2019",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Elaina Gartner",
                    "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
                    "ResponsiblePartyInvestigatorAffiliation": "Barbara Ann Karmanos Cancer Institute"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Barbara Ann Karmanos Cancer Institute",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "National Cancer Institute (NCI)",
                            "CollaboratorClass": "NIH"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.\n\nPURPOSE: This clinical trial is studying how well erlotinib works in treating women undergoing surgery for stage I, stage II, or stage III breast cancer.",
                "DetailedDescription": "OBJECTIVES:\n\nPrimary\n\nTo estimate the effect of erlotinib hydrochloride on expression of interleukin (IL)-1\u03b1 in patients with estrogen receptor (ER-)-negative, EGFR-positive and IL-1\u03b1-positive breast cancer.\n\nSecondary\n\nTo estimate the effect of erlotinib hydrochloride on expression of nuclear NF-\u03baB and amphiregulin (AR) in patients with ER-negative, EGFR-positive and IL-1\u03b1-positive breast cancer.\nTo estimate the effect of erlotinib on tumor cell proliferation (Ki67) and apoptosis (TUNEL).\nTo estimate the rates of IL-1\u03b1, nuclear NF-\u03baB, and AR expression in patients with ER-negative, EGFR-positive breast cancer.\nTo follow the clinical course of patients with resectable ER-negative, EGFR-positive and IL-1\u03b1-positive breast cancer.\nTo assess the toxicity of a 15-day regimen of daily oral administration of erlotinib hydrochloride in participants with ER-negative, EGFR-positive and IL-1\u03b1-positive breast cancer.\n\nOUTLINE: This is an open-label, pilot study. Patients are stratified according to HER2 status (positive vs negative).\n\nPatients receive oral erlotinib hydrochloride once daily on days -14 to 0 in the absence of disease progression or unacceptable toxicity.\n\nPatients undergo surgery on day 0.\n\nTissue samples are collected at baseline and examined for expression of estrogen receptor, progesterone receptor, HER2, EGFR, interleukin (IL)-1\u03b1, amphiregulin, and NF-kB. Tissue samples collected at surgery are examined for IL-1\u03b1, NF-kB, and amphiregulin by IHC.\n\nFollowing surgery, patients will be contacted 1 week post-surgery (\u00b1 1 day) or 1 week post-withdrawal from study (\u00b1 1 day) by phone call or clinic visit to assess toxicity. After that, patients will be followed and treated according to standard of care practices. If patients choose to follow-up with an oncologist outside of our institution, they or their oncologist will be contacted every 6 months for updated information on their conditions."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Breast Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "stage I breast cancer",
                        "recurrent breast cancer",
                        "stage II breast cancer",
                        "stage IIIA breast cancer",
                        "stage IIIB breast cancer",
                        "stage IIIC breast cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Not Applicable"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "44",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "erlotinib hydrochloride",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: erlotinib hydrochloride",
                                    "Other: immunohistochemistry staining method",
                                    "Other: laboratory biomarker analysis",
                                    "Procedure: biopsy",
                                    "Procedure: conventional surgery",
                                    "Procedure: neoadjuvant therapy"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "erlotinib hydrochloride",
                            "InterventionDescription": "Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "erlotinib hydrochloride"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "CP-358,774",
                                    "Erlotinib",
                                    "OSI-774",
                                    "Tarceva"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Other",
                            "InterventionName": "immunohistochemistry staining method",
                            "InterventionDescription": "Assessed at the time of the initial biopsy and at the time of surgery.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "erlotinib hydrochloride"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Other",
                            "InterventionName": "laboratory biomarker analysis",
                            "InterventionDescription": "Correlative studies",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "erlotinib hydrochloride"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Procedure",
                            "InterventionName": "biopsy",
                            "InterventionDescription": "14 days prior to surgery",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "erlotinib hydrochloride"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Procedure",
                            "InterventionName": "conventional surgery",
                            "InterventionDescription": "14 days after taking study drug erlotinib hydrochloride.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "erlotinib hydrochloride"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Procedure",
                            "InterventionName": "neoadjuvant therapy",
                            "InterventionDescription": "14 days after taking study drug erlotinib hydrochloride.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "erlotinib hydrochloride"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Effect of Erlotinib Hydrochloride on Expression of IL-1a in Patients With ER- Negative, EGFR- Positive and (IL-)1a-positive Breast Cancer",
                            "PrimaryOutcomeTimeFrame": "Baseline and day 0"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Effect of Erlotinib Hydrochloride on Expression of NF-\u03baB and AR in Patients With ER-negative, EGFR-positive and IL-1a-positive Breast Cancer",
                            "SecondaryOutcomeTimeFrame": "Baseline and day 0"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Effect of Erlotinib Hydrochloride on Tumor Cell Proliferation (Ki67) and Apoptosis (TUNEL)",
                            "SecondaryOutcomeTimeFrame": "Baseline and day 0"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Toxicity of a 15-day Regimen of Daily Oral Administration of Erlotinib Hydrochloride",
                            "SecondaryOutcomeTimeFrame": "At day -7, prior to surgery, and 1 week post-surgery"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nInclusion\n\nCytologically or histologically confirmed adenocarcinoma of the breast\n\nStage I-III disease\nBI-RADS 4 or 5 abnormalities on breast imaging and undergoing core needle biopsy for diagnosis\nParticipants must have a lesion of at least 1-cm on breast imaging studies (mammogram, ultrasound, or MRI)\n\nParticipants must have breast cancer amenable to surgery with curative intent and must have agreed to undergo such surgery\n\nThe surgical procedure must be scheduled in the near future to accommodate a treatment period of no less and no more than 15 days\nClinically positive for the overexpression of EGFR and interleukin-1\u03b1\n\nClinically negative for expression of the estrogen receptor (ER-negative) and progesterone receptor (PgR-negative)\n\nMay be positive or negative for HER2\n\nExclusion\n\nLocally advanced or metastatic disease not amenable to surgery\nKnown brain metastases\n\nPATIENT CHARACTERISTICS:\n\nInclusion\n\nFemale\nMenopausal status not specified\nECOG performance status (PS) 0-2 or Karnofsky PS 60-100%\nANC \u2265 1000/mm\u00b3\nPlatelet count \u2265 75,000/mm\u00b3\nAST and ALT \u2264 2.5 times upper limits of normal (ULN)\nAlkaline phosphatase \u2264 2.5 times ULN\nBilirubin \u2264 2 times ULN\nHemoglobin > 9 g/dL\nCreatinine within normal institutional limits OR creatinine clearance >60 mL/min\nNegative serum pregnancy test within 7 days of enrollment for pre-menopausal women and women within 6 months of menopause\nWomen of child-bearing potential and their partners must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation\n\nExclusion\n\nPregnant or nursing\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib hydrochloride\n\nUncontrolled intercurrent illness including, but not limited to, any of the following:\n\nOngoing or active infection\nSymptomatic congestive heart failure\nUnstable angina pectoris\nCardiac arrhythmia\nPsychiatric illness/social situations that would limit compliance with study requirements\n\nPRIOR CONCURRENT THERAPY:\n\nExclusion\n\nReceived any other therapy (i.e., surgery, radiation, hormone treatment, biologic therapy, and/or chemotherapy) for the treatment of breast cancer\nConcurrent use of anti-neoplastic or anti-tumor agents not part of the study therapy, including chemotherapy, radiation therapy, immunotherapy, and hormonal anticancer therapy\nReceiving any other investigational agents",
                "HealthyVolunteers": "No",
                "Gender": "Female",
                "MinimumAge": "18 Years",
                "MaximumAge": "120 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Elaina M. Gartner, MD",
                            "OverallOfficialAffiliation": "Barbara Ann Karmanos Cancer Institute",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Barbara Ann Karmanos Cancer Institute",
                            "LocationCity": "Detroit",
                            "LocationState": "Michigan",
                            "LocationZip": "48201-1379",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            },
            "ReferencesModule": {
                "SeeAlsoLinkList": {
                    "SeeAlsoLink": [
                        {
                            "SeeAlsoLinkLabel": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database",
                            "SeeAlsoLinkURL": "http://cancer.gov/clinicaltrials"
                        }
                    ]
                }
            }
        },
        "ResultsSection": {
            "ParticipantFlowModule": {
                "FlowPreAssignmentDetails": "All participants that signed consent were screen failures.",
                "FlowRecruitmentDetails": "44 participants signed consent starting 1-9-08 and recruitment ending with the last participant signing on 1-19-10. All participants enrolled onto screening portion of study, but none were ever put onto the \"treatment\" portion of the study.",
                "FlowGroupList": {
                    "FlowGroup": [
                        {
                            "FlowGroupId": "FG000",
                            "FlowGroupTitle": "Erlotinib Hydrochloride",
                            "FlowGroupDescription": "If participants would have went onto study they would receive erlotinib(Tarceva\u00ae)hydrochloride 150 mg/day starting dose PO (orally) self-administered, QD (every day) on days -14 until day 0 immediately prior to scheduled surgery, Tissue sent for biomarker modulation analysis\n\nTreatment continues in the absence of disease progression or unacceptable toxicity.\n\nBiomarker analysis performed, toxicity monitored for 7 days following last dose of erlotinib (Tarceva\u00ae)"
                        }
                    ]
                },
                "FlowPeriodList": {
                    "FlowPeriod": [
                        {
                            "FlowPeriodTitle": "Overall Study",
                            "FlowMilestoneList": {
                                "FlowMilestone": [
                                    {
                                        "FlowMilestoneType": "STARTED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "44"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "0"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "NOT COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "44"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "FlowDropWithdrawList": {
                                "FlowDropWithdraw": [
                                    {
                                        "FlowDropWithdrawType": "All screen failures",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "44"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "BaselineCharacteristicsModule": {
                "BaselineGroupList": {
                    "BaselineGroup": [
                        {
                            "BaselineGroupId": "BG000",
                            "BaselineGroupTitle": "Erlotinib Hydrochloride",
                            "BaselineGroupDescription": "If participants would have went onto study they would receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity."
                        }
                    ]
                },
                "BaselineDenomList": {
                    "BaselineDenom": [
                        {
                            "BaselineDenomUnits": "Participants",
                            "BaselineDenomCountList": {
                                "BaselineDenomCount": [
                                    {
                                        "BaselineDenomCountGroupId": "BG000",
                                        "BaselineDenomCountValue": "44"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "BaselineMeasureList": {
                    "BaselineMeasure": [
                        {
                            "BaselineMeasureTitle": "Age, Categorical",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "<=18 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Between 18 and 65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "37"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": ">=65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "7"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Age, Continuous",
                            "BaselineMeasureParamType": "Median",
                            "BaselineMeasureDispersionType": "Full Range",
                            "BaselineMeasureUnitOfMeasure": "years",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "52",
                                                                "BaselineMeasurementLowerLimit": "24",
                                                                "BaselineMeasurementUpperLimit": "79"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sex: Female, Male",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Female",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "44"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Male",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Region of Enrollment",
                            "BaselineMeasureParamType": "Number",
                            "BaselineMeasureUnitOfMeasure": "participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineClassTitle": "United States",
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "44"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomeMeasuresModule": {
                "OutcomeMeasureList": {
                    "OutcomeMeasure": [
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Effect of Erlotinib Hydrochloride on Expression of IL-1a in Patients With ER- Negative, EGFR- Positive and (IL-)1a-positive Breast Cancer",
                            "OutcomeMeasurePopulationDescription": "No participants received the study drug erlotinib hydrochloride.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "Baseline and day 0",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Erlotinib Hydrochloride",
                                        "OutcomeGroupDescription": "Patients must be willing to consider treatment with erlotinib, in the event they are eligible for the treatment phase of the study. Erlotinib (Tarceva\u00ae) will be self-administered in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single-agent erlotinib (Tarceva\u00ae), at a dose of 150 mg/day mg by mouth. Patients will be instructed to take tablets once daily. The day of planned surgical resection of the invasive breast cancer will be considered day 0. Patients will undergo baseline physical examination and performance status evaluation on or before day -14. Patients will begin treatment with erlotinib 150 mg (1 tablet) orally daily on day -14 and it will be continued for a total of 15 days, through day 0."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Effect of Erlotinib Hydrochloride on Expression of NF-\u03baB and AR in Patients With ER-negative, EGFR-positive and IL-1a-positive Breast Cancer",
                            "OutcomeMeasurePopulationDescription": "No data collected for secondary hypotheses.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "Baseline and day 0",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Erlotinib Hydrochloride",
                                        "OutcomeGroupDescription": "Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nerlotinib hydrochloride: Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nimmunohistochemistry staining method: Assessed at the time of the initial biopsy and at the time of surgery.\n\nlaboratory biomarker analysis: Correlative studies\n\nbiopsy: 14 days prior to surgery\n\nconventional surgery: 14 days after taking study drug erlotinib hydrochloride.\n\nneoadjuvant therapy: 14 days after taking study drug erlotinib hydrochloride."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Effect of Erlotinib Hydrochloride on Tumor Cell Proliferation (Ki67) and Apoptosis (TUNEL)",
                            "OutcomeMeasurePopulationDescription": "No data collected for secondary hypotheses.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "Baseline and day 0",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Erlotinib Hydrochloride",
                                        "OutcomeGroupDescription": "If participants would have went onto study they would receive erlotinib(Tarceva\u00ae)hydrochloride 150 mg/day starting dose PO (orally) self-administered, QD (every day) on days -14 until day 0 immediately prior to scheduled surgery, Tissue sent for biomarker modulation analysis\n\nTreatment continues in the absence of disease progression or unacceptable toxicity.\n\nBiomarker analysis performed, toxicity monitored for 7 days following last dose of erlotinib (Tarceva\u00ae)"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Toxicity of a 15-day Regimen of Daily Oral Administration of Erlotinib Hydrochloride",
                            "OutcomeMeasurePopulationDescription": "No data collected for secondary hypotheses.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "At day -7, prior to surgery, and 1 week post-surgery",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Erlotinib Hydrochloride",
                                        "OutcomeGroupDescription": "If participants would have went onto study they would receive erlotinib(Tarceva\u00ae)hydrochloride 150 mg/day starting dose PO (orally) self-administered, QD (every day) on days -14 until day 0 immediately prior to scheduled surgery, Tissue sent for biomarker modulation analysis\n\nTreatment continues in the absence of disease progression or unacceptable toxicity.\n\nBiomarker analysis performed, toxicity monitored for 7 days following last dose of erlotinib (Tarceva\u00ae)"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "AdverseEventsModule": {
                "EventsFrequencyThreshold": "0",
                "EventsDescription": "No patients were actually treated on the study.",
                "EventGroupList": {
                    "EventGroup": [
                        {
                            "EventGroupId": "EG000",
                            "EventGroupTitle": "Erlotinib Hydrochloride",
                            "EventGroupDescription": "Patients will be instructed to take tablets once daily.Patients will begin treatment with erlotinib 150 mg (1 tablet) orally daily on day -14 and it will be continued for a total of 15 days, through day 0.The day of planned surgical resection of the invasive breast cancer will be considered day 0.",
                            "EventGroupSeriousNumAffected": "0",
                            "EventGroupSeriousNumAtRisk": "0",
                            "EventGroupOtherNumAffected": "0",
                            "EventGroupOtherNumAtRisk": "0"
                        }
                    ]
                }
            },
            "MoreInfoModule": {
                "CertainAgreement": {
                    "AgreementPISponsorEmployee": "Yes",
                    "AgreementRestrictiveAgreement": "No"
                },
                "PointOfContact": {
                    "PointOfContactTitle": "Dr. Elaina Gartner",
                    "PointOfContactOrganization": "Barbara Ann Karmanos Cancer Institute",
                    "PointOfContactEMail": "egartner@seagen.com",
                    "PointOfContactPhone": "313-576-8724"
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M14540",
                            "ConditionBrowseLeafName": "Recurrence",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000069347",
                            "InterventionMeshTerm": "Erlotinib Hydrochloride"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000047428",
                            "InterventionAncestorTerm": "Protein Kinase Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000004791",
                            "InterventionAncestorTerm": "Enzyme Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M11590",
                            "InterventionBrowseLeafName": "Mitogens",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M398",
                            "InterventionBrowseLeafName": "Erlotinib Hydrochloride",
                            "InterventionBrowseLeafAsFound": "Phase 2",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M7806",
                            "InterventionBrowseLeafName": "Estrogens",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M25510",
                            "InterventionBrowseLeafName": "Protein Kinase Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7641",
                            "InterventionBrowseLeafName": "Enzyme Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        }
                    ]
                }
            }
        }
    }
}